PRCT is a robotic surgery company with a similar early-stage revenue trajectory to ISRG (which grew to $140B), currently trading at 2.3x estimated 2028 revenues of $475M. Key risks include execution risk on revenue projections, competition in robotic surgery market, profitability uncertainty, and the high volatility typical of early-stage medical device companies.